Safety of Anal Curcumin
NCT06626230
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgical excision (cutting out the abnormal cells)), which have potential short- and long-term side effects.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Anal High Grade Squamous Intraepithelial Lesion
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Lisa Flowers
- Last updated on ClinicalTrials.gov
- August 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 2
- Grady Hospital - Ponce De Leon Clinic · Atlanta, GA
- Grady Memorial Hospital · Atlanta, GA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.